Life Sciences Leadership Summit
June 15, 2011
June 15, 2011
Washington State University
Spokane, WA
Read More
Washington State Preferred Drug List and the Therapeutic Interchange Program (TIP)
June 15, 2011
The Therapeutic Interchange Program (TIP) has developed a process allowing physicians and other prescribers to endorse the Washington State Preferred Drug List (PDL), and requires pharmacists to automatically substitute the preferred drug for non preferred drugs prescribed by these practitioners unless the prescription is for a refill of an antipsychotic, antidepressant, chemotherapy, antiretroviral, or immunosuppressive drug, in which case the pharmacist shall dispense the prescribed non preferred drug.
Read More.
Washington State Legislature – Therapeutic Interchange Program
June 15, 2011
This section contains the department’s rules for the endorsing practitioner therapeutic interchange program (TIP). TIP is established under RCW. The statutes require state-operated prescription drug programs to allow physicians and other prescribers to endorse a Washington preferred drug list (PDL) and, in most cases, requires pharmacists to automatically substitute a preferred, equivalent drug from the list.
Read More.
Washington State Legislature – Therapeutic Interchange Program
June 15, 2011
This section contains the department’s rules for the endorsing practitioner therapeutic interchange program (TIP). TIP is established under RCW. The statutes require state-operated prescription drug programs to allow physicians and other prescribers to endorse a Washington preferred drug list (PDL) and, in most cases, requires pharmacists to automatically substitute a preferred, equivalent drug from the list.
Read More.
Why Biotechs Need To Worry About Generics, Too.
June 14, 2011
By Brian Gormley
Wall Street Journal
U.S. pharmaceutical companies have long lived with generic rivals, and soon biotechnology concerns will face similar competition. Through the health-care reform law passed last year, Congress created a regulatory path for companies to introduce “biosimilars,” or nearly exact copies of biological drugs that have come off patent. Read More
When It Comes to Patient Safety, Caution Isn’t a Four-letter Word
May 20, 2011
By Jorgo Chatzimarkakis, PhD, member of European Parliament
The Health Care Blog
Around the world and now in the United States, there is a broadening discussion of how best to proceed down the path of approving and getting to market medicines called biosimilars. Biosimilars are non-identical copies of next generation medicines known as biologics. As the U.S. begins establishing new guidance for biosimilars, regulators and legislators should look to the European Union model on guidance policy and approve these important, often life-saving, drugs when they are proven to be safe for the patients they are intended to heal. Read More
When It Comes to Patient Safety, Caution Isn’t a Four-letter Word
May 20, 2011
By Jorgo Chatzimarkakis, PhD, member of European Parliament
The Health Care Blog
Around the world and now in the United States, there is a broadening discussion of how best to proceed down the path of approving and getting to market medicines called biosimilars. Biosimilars are non-identical copies of next generation medicines known as biologics. As the U.S. begins establishing new guidance for biosimilars, regulators and legislators should look to the European Union model on guidance policy and approve these important, often life-saving, drugs when they are proven to be safe for the patients they are intended to heal. Read More
FDA’s Rush in Generic Drug Testing Could Harm Patients
May 19, 2011
By Andre Williams, Association of Black Cardiologists
Politic365.com
President Barack Obama recently indicated his interest in improving the Food and Drug Administration’s (FDA) approval process for new medical devices, saying the agency could “keep patients safer while getting innovative and life-saving products to market faster.” Read More
FDA’s Rush in Generic Drug Testing Could Harm Patients
May 19, 2011
By Andre Williams, Association of Black Cardiologists
Politic365.com
President Barack Obama recently indicated his interest in improving the Food and Drug Administration’s (FDA) approval process for new medical devices, saying the agency could “keep patients safer while getting innovative and life-saving products to market faster.” Read More
Initial Biotechnology Drug Copies May Get Brand-Name Fees
May 10, 2011
Drugmakers seeking U.S. approval for the first lower-cost copies of biologic medicines made from living cells should initially pay application fees similar to charges for brand-name medicines, regulators said. Read More
